Acro Biomedical Co., Ltd.
ACBM· OTC
ACBMAcro Biomedical Co., Ltd.
Filed Apr 2, 2021 · 10-K · 92 days after period end · 0001640334-21-000767
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $193.54K | $1.35M | — |
| Net Income | -$61.77K | -$75.87K | -$75.02K | $39.50K |
| EPS Diluted | — | $0.00 | $0.00 | — |
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Apr 2, 2021 · 92 d after period end
